Clinical Trial Update: Induction Chemotherapy for MRF-negative, Moderate-risk, Resectable Middle and Low Rectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on induction chemotherapy for MRF-negative, moderate-risk, resectable middle and low rectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Rectal Cancer | Phase 2 | Status: UNKNOWN